Structural imaging remains an essential component of diagnosis, staging and response
assessment in patients with cancer; however, as clinicians increasingly seek to …

This review traces the development of targeted radionuclide therapy (TRT)(the Magic Bullet)
from the discovery of radioactivity in nature and the subsequent discovery of artificial …

Conventional external-beam radiation therapy is dedicated to the treatment of localized
disease, whereas radioimmunotherapy represents an innovative tool for the treatment of …

Although use of the term “theranostic” is relatively recent, the concept goes back to the
earliest days of nuclear medicine, with the use of radioiodine for diagnosis and therapy of …

Radioimmunotherapy (RIT) is FDA-approved for the clinical management of liquid
malignancies, however, its use for solid malignancies remains a challenge. The putative …

Targeted therapeutics such as monoclonal antibodies (mAbs) have proven successful as
cancer drugs. To profile products that could be marketed in the future, we examined the …

Lutetium 177 (177Lu) DOTA-0-Tyr3-Octreotate (DOTATATE) peptide receptor radionuclide
therapy (PRRT) is an effective treatment for advanced gastroenteropancreatic …

The approval of 223 RaCl 2 for cancer therapy in 2013 has heralded a resurgence of
interest in the development of α-particle emitting radiopharmaceuticals. In the last decade …

Therapy of cancer with radiolabeled monoclonal antibodies has produced impressive
results in preclinical experiments and in clinical trials conducted in radiosensitive …

Non-Hodgkin's lymphoma (NHL) comprises a clinically and biologically heterogeneous
group of lymphoproliferative disorders originating in B lymphocytes, T lymphocytes, or …